Immunoconjugates and methods
US11806405B1 · kind B1 · utility
5Cited by
49References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2022 |
| Grant date | Nov 7, 2023 |
| Priority date | — |
| Expiry date | Sep 28, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer. Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n (I)
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.